



Clayton, NC
Manufacturing Facilities



ESTABLISHED IN 1993



MORE THAN 1,200
EMPLOYEES

Novo Nordisk in North Carolina

For a quarter century, Clayton, North Carolina, has been home to one of Novo Nordisk's U.S. manufacturing facilities. Currently, Novo Nordisk is investing \$2 billion in a new active pharmaceutical ingredient (API) production facility in Clayton. The expansion is considered the largest single manufacturing economic development investment in state history and will help Novo Nordisk meet the increasing global demand for our diabetes medicines.

Our current diabetes finished products facility

In addition to the API production facility that is currently under construction, our 464,602 square foot aseptic manufacturing facility in Clayton currently employs more than 800 people. The facility is part of a global network of manufacturing sites responsible for several key steps in the diabetes and obesity treatment manufacturing process, including aseptic formulation, filling, inspection, assembly, and packaging.

The facility supports 24/7 continuous operations with four dedicated day and night shift production teams, as well as on-site engineers, quality professionals and administrative staff in areas like HR, Finance, Accounting, IT, and Supply Chain Procurement.



Trinity Alfaro
Type 1 Diabetes

MILESTONES

- 1996: First vial batches shipped
- 1998: First cartridge batches shipped
- 2007: FlexPen® assembly and packaging
- 2015: FlexTouch® assembly and packaging
- 2016: Groundbreaking of Diabetes Active Pharmaceutical Ingredients U.S. facility
- 2017: Hired 1,000th employee
- 2019: Acquired Durham facility



19% OF EMPLOYEES ARE VETERANS



Rutha Gordon
Type 2 Diabetes

SUPPLIER RELATIONS WITH 247 SMALL BUSINESSES

- Female owned
- Veteran owned
- Minority owned

Expansions

Once complete, the new API production facility will measure 825,000 square feet and have a footprint of 95 acres — the equivalent to approximately seven football fields. It will be the first location outside of Denmark where Novo Nordisk diabetes active pharmaceutical ingredients (API) will be produced. This expansion is expected to create hundreds of jobs once fully operational. The new facility is expected to be approved to produce for the U.S. market in 2021.

In 2019, Novo Nordisk acquired a tableting and packaging facility in Durham, North Carolina. We look forward to further collaboration in the state as a member of and employer in the Durham community.

Economic impact

Novo Nordisk's North Carolina facilities function with the help of nearly 300 local suppliers and vendors, with a total annual expenditure of more than \$105 million in 2019. We have supplier relationships with 247 small businesses, including female-, veteran- and minority-owned businesses. Additionally, we have paid a total of \$5.8 million in property tax to Johnston, Buncombe, and Durham Counties in 2019.

MORE THAN
\$5.8 MILLION IN
PROPERTY TAX



CONTRIBUTED TO
JOHNSTON, BUNCOMBE,
AND DURHAM COUNTIES
IN 2019



Sabrina Coley
Work Cell Leader



AWARDS AND RECOGNITIONS

- North Carolina Department of Labor
2 Million Hour Safety Award
- FORTUNE 100 Best Companies to Work For® since 2009
- Carolina Parenting Magazine Top 50 Family-Friendly Workplaces
- Triangle Business Journal Leaders in Diversity Award
- Employer Support of the Guard & Reserve Patriot Award
- Triangle Business Journal Healthiest Employer Award, 2018




P.J. Pimpinelli
Type 1 Diabetes



Jagruti Pandya
Type 2 Diabetes



Kristal Troy
Manager, Chemistry



Natasha Crawford
Manufacturing Process Technician

Tammy Boyd
Work Cell Leader

For the community

We are parents, colleagues, neighbors and friends—people living with the complexities of serious diseases. And we believe in the combination of science and soul to help nurture each other back to good health. We live this mission at Novo Nordisk every day to benefit patients, their families, as well as the broader community.

Novo Nordisk is committed to making a difference in North Carolina. We partner with policy makers to address the community's needs for improved diabetes and obesity care and provide support for and partner with organizations that share similar visions and goals. Other organizations we work with on the front lines include:

- Johnston Community College and Johnston County Workforce Development Center Board of Trustees, Scholarship Fund, and In-Kind Donations
- North Carolina State University Biotechnology Education Center, Center for Innovation Management Studies, and Women's Center
- JDRF, North Carolina Triangle Chapter annual fundraising initiatives and advisory board
- United Way of the Greater Triangle annual fundraising initiatives
- Carolina Hurricanes Presenting Sponsor of the Power Play youth fitness program
- Johnston Health Foundation Healthy Kids Fund and advisory board
- Clayton Chamber of Commerce Champion Sponsor, Advisory Board and Workforce Development Committee
- JoCo Works Presenting Sponsor
- Durham Chamber of Commerce
- Biomanufacturing Research Institute & Technology Enterprise (BRITE) at NC Central University

About Novo Nordisk in the U.S.:

Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases, including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 employees throughout the country. For more information, visit novonordisk.us, Facebook, Twitter, and Instagram.

STAY CONNECTED



For more information about Novo Nordisk's North Carolina location, visit: novonordisk.us and select Clayton, NC under "US Locations."

Clinical research partnerships

We believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation and bringing next generations of safe and effective medicines to our patients. Clinical activity conducted in North Carolina includes collaborating directly with investigators at institutions such as the University of North Carolina, UNC Diabetes Care Center.

Environmental Sustainability

Novo Nordisk's focus is to be a sustainable business. Our Triple Bottom Line (TBL) principle is anchored in the way we do business, ensuring that our decisions balance financial, environmental and socially responsible considerations while always keeping in mind the best interests of the patients we serve.

Novo Nordisk in North Carolina is involved in a variety of sustainability efforts, including:

- Implementing systems to support reusing, recycling and repurposing water and other raw materials
- \$70 million investment in a solar panel installation in Pender County, NC, that provides renewable electricity to all Novo Nordisk offices, laboratories and manufacturing facilities in the U.S.



Novo Nordisk Inc., 800 Scudders Mill Rd., Plainsboro, NJ 08536 U.S.A.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
©2020 Novo Nordisk US20NNG00055 Last Updated: July 2020